Donanemab + Nivegacetor for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 May 2025: Trial registered, NCT06996730
  2. 8 Jul 2026: Trial started, NCT06996730

The trials

NCT06996730: A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

State
Under way
Phase
Phase 2 and Phase 3
People
240 planned
Started
8 Jul 2026
Primary completion
1 Jun 2030
Arms
Part 2: RG6289 plus donanemab
Results
None posted
  1. 30 May 2025: Trial registered
  2. 8 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.